Why is Epitalon on the FDA PCAC July 2026 docket?

Epitalon is scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) review on July 24, 2026 because its current 503A bulk drug substance classification is Category 2 — a holding status indicating the committee previously found questions warranting further evaluation rather than immediately supporting positive listing. The PCAC review will assess whether Epitalon meets the criteria for Category 1 (positive listing, allowing continued 503A compounding), should be maintained at Category 2, or should be restricted from 503A compounding use. The outcome directly determines whether 503A compounding pharmacies may legally continue preparing Epitalon under patient-specific prescriptions. No FDA-approved pharmaceutical equivalent of Epitalon exists, making the 503A channel the only regulated domestic source.

How does Epitalon relate to Epithalamin and other Khavinson bioregulator peptides?

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed as the synthetic analogue of Epithalamin, a natural peptide extract derived from bovine pineal gland tissue that was used in early Khavinson bioregulator research in the Soviet era. Epithalamin itself is not a single defined compound but a complex mixture of pineal peptides; Epitalon represents an attempt to isolate and synthesize the active tetrapeptide motif in a chemically defined form. The Khavinson bioregulator research tradition includes multiple organ-specific peptides following a similar development pattern: Pinealon (Val-Glu-Asp, from pineal tissue, investigated in neurological contexts) and Cortagen (Ala-Glu-Asp-Pro, from cerebral cortex, investigated in neuroprotective contexts) are structural relatives. All three are under consideration in the broader 2026 PCAC review cycle. See the [Epitalon, Pinealon, and Cortagen comparison article](/blog/epitalon-pinealon-cortagen-bioregulator-family/) for a detailed mechanism and evidence comparison.

Epitalon FDA PCAC July 2026: 503A Review and Research Access

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to convene on July 24, 2026 to evaluate the 503A bulk drug substance status of Epitalon (Epithalon). For researchers who have used 503A compounding pharmacies as the domestic regulated source of this tetrapeptide, the committee's determination will directly affect continued access. This article explains Epitalon's research history, its 503A regulatory position, and the factors the PCAC will weigh in its July 24 evaluation.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and regulatory documentation. It does not constitute medical or legal advice. See the Epitalon compound library profile for full compound data, and the PCAC overview article for context on all compounds under review.

What Epitalon is and why it is compounded

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, beginning in the 1980s. The compound is a synthetic analogue of Epithalamin, a natural peptide extract of the pineal gland, and has been investigated primarily in contexts related to aging biology, telomere maintenance, and circadian-neuroendocrine regulation.

Epitalon's most widely cited proposed mechanism involves activation of telomerase — the enzyme responsible for maintaining telomere length in dividing cells. Khavinson et al. (2003, Bulletin of Experimental Biology and Medicine) reported that Epitalon treatment increased telomerase activity in human fetal fibroblasts in culture, with associated elongation of telomere length in treated cells relative to controls. This finding — that a short synthetic peptide could activate endogenous telomerase in human cells — generated substantial research interest and has been cited extensively in the longevity and aging-biology literature.

Because no FDA-approved pharmaceutical preparation of Epitalon exists, its clinical and investigational use in the United States has relied on Section 503A compounding pharmacies. The July 24, 2026 PCAC review determines whether that channel continues.

The 503A framework and Epitalon's current classification

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies preparing patient-specific prescriptions. The law requires use of bulk drug substances from an FDA-maintained positive list, FDA-approved drug components, or substances meeting specified alternative criteria. The PCAC advises FDA on which bulk drug substances should be listed, maintained, or restricted.

Epitalon is currently under 503A Category 2 review — placed in a holding position pending advisory committee evaluation, as with the other peptides in the July 2026 docket. The July 24 meeting is the formal evaluation opportunity for nominators who have submitted clinical need documentation and updated evidence.

The research evidence base

Telomere and cellular aging research: The centerpiece of the Epitalon research literature is telomerase activation. Khavinson et al. (2003) reported telomerase activity increases and telomere length extension in human fetal fibroblast cell cultures treated with Epitalon. Subsequent work from the same group examined Epitalon in aged tissue models and in the context of chromosomal stability. This research has been conducted primarily by the Khavinson group and associated St. Petersburg laboratories — a concentration of authorship that is acknowledged in critical reviews of the literature.

Pineal and circadian regulation: Epitalon has been investigated for effects on melatonin secretion and circadian function, consistent with its origin as an analogue of pineal-derived Epithalamin. Korkushko et al. (2006, Bulletin of Experimental Biology and Medicine) reported that peptide bioregulator treatment — including Epitalon — in elderly individuals was associated with improved melatonin secretion profiles and reduced markers of biological age in longitudinal cohort studies. These studies are methodologically distinct from placebo-controlled RCTs and represent observational data.

Anti-tumor and longevity research in animal models: The Khavinson group and Anisimov's laboratory at the N.N. Petrov Research Institute of Oncology have published studies examining Epitalon's effects on tumor incidence and lifespan in aging rodent models. Anisimov et al. (2003, Annals of the New York Academy of Sciences) reported reduced spontaneous mammary tumor incidence and extended mean lifespan in Epitalon-treated female rats compared to controls. These are animal model findings and have not been replicated in human RCTs.

Human studies: Epitalon appears in a small number of human observational studies from Soviet and Russian institutions examining peptide bioregulator effects in aging populations. These studies — primarily published in Bulletin of Experimental Biology and Medicine — involve small cohorts, lack rigorous blinding, and fall well below the evidentiary standard for FDA drug approval. They represent the totality of available human evidence.

Independent replication: The core telomerase-activation finding and the longevity claims have not been extensively replicated by independent research groups outside the Khavinson-affiliated research network. This is a recognized limitation of the Epitalon evidence base that the PCAC is likely to consider under Factor 2.

The no-approved-equivalent argument

No FDA-approved drug contains Epitalon as an active ingredient. No NDA or ANDA referencing Epitalon exists in FDA's drug database. The compound exists exclusively within the research and compounding channels. This absence of a commercial approved equivalent is Epitalon's strongest regulatory argument for continued 503A availability, consistent with the same argument applicable to the other PCAC July 2026 compounds.

The committee will assess whether approved anti-aging or longevity-related therapeutics — if any are considered applicable — constitute suitable substitutes. Because no FDA-approved drug has an approved indication for longevity, telomere maintenance, or biological aging per se, the "suitable commercial alternative" analysis may weigh favorably for Epitalon in this respect.

What the PCAC evaluates: four-factor analysis applied to Epitalon

Factor 1 — Physical and chemical characteristics: Epitalon is a tetrapeptide of approximately 390 Da molecular weight with good water solubility. It is compounded as a lyophilized powder for reconstitution and subcutaneous injection, a formulation format common to the short-peptide bioregulator class. Stability data across storage conditions will form part of the committee record.

Factor 2 — Safety and effectiveness evidence: The safety record is favorable across published literature with no significant toxicological signals in rodent studies. The effectiveness record is concentrated in the Khavinson group's publications, with the telomerase-activation finding as the primary mechanistic anchor and animal lifespan studies as supporting evidence. The limited independent replication is the primary vulnerability in this analysis.

Factor 3 — Historical use in compounding: Epitalon has documented prescribing history through 503A compounders in anti-aging, longevity, and circadian regulation contexts. The volume and duration of this use will be presented to the committee.

Factor 4 — Nature of the condition treated: The clinical contexts in which Epitalon is compounded — primarily aging-related conditions, circadian dysregulation, and longevity-oriented interventions — are not served by FDA-approved equivalents with equivalent mechanisms. The committee will weigh whether these contexts represent sufficient clinical need to support positive listing.

Outcome scenarios following July 24, 2026

Scenario A — Upgraded to Category 1. The committee accepts the telomerase-activation evidence and animal model data as meeting the 503A plausibility standard, finds no adequate commercial substitute, and recommends positive listing. 503A pharmacies may continue compounding Epitalon.

Scenario B — Maintained at Category 2. Evidence is found insufficient for positive listing — particularly given the single-group research concentration — but not clearly adverse. Continued compounding availability in the near term with ongoing uncertainty.

Scenario C — Restricted or prohibited. If the committee recommends exclusion, and FDA finalizes that recommendation, 503A pharmacies could not use Epitalon as a bulk drug substance. This would effectively end domestic compounded access.

Regulatory timeline

An advisory committee recommendation is not a final regulatory action. Following July 24, FDA will open a public comment period before issuing a formal determination. The timeline from PCAC meeting to final agency action has historically ranged from six months to over one year. Researchers and institutions with a stake in the outcome have standing to submit comments during that window.

Summary

Epitalon's July 24, 2026 PCAC review will turn primarily on whether the committee accepts the Khavinson group's telomerase-activation findings and animal longevity data as meeting the 503A evidentiary threshold for clinical plausibility, in the absence of extensive independent replication. The complete absence of any FDA-approved equivalent containing Epitalon remains its strongest regulatory argument. The research interest in the compound — particularly within the anti-aging research community — is reflected in its documented compounding history and the body of nominators supporting positive listing.

For full compound chemistry, mechanism data, and preclinical literature, see the Epitalon compound library profile. For comparison with Humanin and its mitochondrial companion compounds, see Epitalon vs Humanin. For the broader July 2026 PCAC context, see the PCAC overview article.